A novel 5HT3 antagonist 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide) prevents diabetes-induced depressive phenotypes in mice: Modulation of serotonergic system

Behavioural Brain Research

Volumn 297, Issue , 2016, Pages 41-50

  Gupta, Deepali ^a   Thangaraj, Devadoss ^b   Radhakrishnan, Mahesh ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^b KVSR SIDDHARTHA COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

5HT3 receptor antagonist; Depressive phenotypes; Diabetes; Forced swim test; Open field test; Serotonin

Indexed keywords

1 (3 CHLOROPHENYL)BIGUANIDE; FLUOXETINE; N (3 CHLORO 2 METHYLPHENYL)QUINOXALIN 2 CARBOXAMIDE; SEROTONIN 3 ANTAGONIST; STREPTOZOCIN; UNCLASSIFIED DRUG; 1-(3-CHLOROPHENYL)BIGUANIDE; ANTIDEPRESSANT AGENT; BIGUANIDE DERIVATIVE; N-(3-CHLORO-2-METHYLPHENYL)QUINOXALIN-2-CARBOXAMIDE; QUINOXALINE DERIVATIVE; SEROTONIN; SEROTONIN 3 AGONIST; SEROTONIN 3 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BRAIN REGION; CEREBELLUM; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG STRUCTURE; FORCED SWIM TEST; MALE; MESENCEPHALON; MOUSE; NONHUMAN; OPEN FIELD TEST; PREFRONTAL CORTEX; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL; SEROTONINERGIC SYSTEM; SOCIAL INTERACTION TEST; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TREATMENT DURATION; ANIMAL; BRAIN; CHEMISTRY; COMPLICATION; DEPRESSIVE DISORDER; DIABETES MELLITUS, EXPERIMENTAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; PRECLINICAL STUDY; PSYCHOLOGY; RANDOMIZATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIGUANIDES; BRAIN; DEPRESSIVE DISORDER; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FLUOXETINE; MALE; MICE; QUINOXALINES; RANDOM ALLOCATION; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN; SEROTONIN 5-HT3 RECEPTOR AGONISTS; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS;

EID: 84944111549     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.10.007     Document Type: Article

References (51)

1. Egede L.E., Zheng D. Independent factors associated with major depressive disorder in a national sample of individuals with diabetes. Diabetes Care 2003, 26:104-111.
2. Grigsby A.B., Anderson R.J., Freedland K.E., Clouse R.E., Lustman P.J. Prevalence of anxiety in adults with diabetes: a systematic review. J. Psychosom. Res. 2002, 53:1053-1060.
3. Talbot F., Nouwen A., Gingras J., Gosselin M., Audet J. The assessment of diabetes-related cognitive and social factors: the Multidimensional Diabetes Questionnaire. J. Behav. Med. 1997, 20:291-312.
4. Gupta D., Kurhe Y., Radhakrishnan M. Antidepressant effects of insulin in streptozotocin induced diabetic mice: modulation of brain serotonin system. Physiol. Behav. 2014, 129:73-78.
5. Gupta D., Radhakrishnan M., Kurhe Y. Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system. Eur. J. Pharmacol. 2014, 744:59-66.
6. Yamato T., Misumi Y., Yamasaki S., Kino M., Aomine M. Diabetes mellitus decreases hippocampal release of neurotransmitters: an in vivo microdialysis study of awake, freely moving rats. Diabetes Nutr. Metab. 2004, 17:128-136.
7. Mackenzie R.G., Trulson M.E. Effects of insulin and streptozotocin induced diabetes on brain tryptophan and serotonin metabolism in rats. J. Neurochem. 1978, 30:205-211.
8. Shpakov A., Chistyakova O., Derkach K., Bondareva V. Hormonal signaling systems of the brain in diabetes mellitus. Neurodegenerative Diseases 2011, 349-386. Intech Open Access Publisher, Rijeka, Croatia. R.C. Chang (Ed.).
9. Goodnick P.J. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann. Clin. Psychiatry 2001, 13:31-41.
10. Gumnick J.F., Nemeroff C.B. Problems with currently available antidepressants. J. Clin. Psychiatry 2000, 61:5-15.
11. Masand P.S. Tolerability and adherence issues in antidepressant therapy. Clin. Ther. 2003, 25:2289-2304.
12. Robinson M.J. Antidepressant psychopharmacology: current limitations and future directions. Prim. Psychiatry 2003, 10:43-49.
13. Lustman P.J., Griffith L.S., Clouse R.E., Freedland K.E., Eisen S.A., Rubin E.H., et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom. Med. 1997, 59:241-250.
14. Carvalho F., Barros D., Silva J., Rezende E., Soares M., Fregoneze J., et al. Hyperglycemia induced by pharmacological activation of central serotonergic pathways depends on the functional integrity of brain CRH system and 5-HT3 receptors. Horm. Metab. Res. 2004, 37:482-488.
15. Moosa M.Y., Panz V.R., Jeenah F.Y., Joffe B.I. African women with depression: the effect of imipramine and fluoxetine on body mass index and leptin secretion. J. Clin. Psychopharmacol. 2003, 23:549-552.
16. Laimer M., Kramer-Reinstadler K., Rauchenzauner M., Lechner-Schoner T., Strauss R., Engl J., et al. Effect of mirtazapine treatment on body composition and metabolism. J. Clin. Psychiatry 2006, 67:421-424.
17. Chen W.Y., Chen C.C., Hung G.C. Hyperglycemic hyperosmolar state associated with low-dose quetiapine treatment in a patient with bipolar disorder. Curr. Drug Saf. 2011, 6:207-208.
18. Gehlert D.R., Shaw J. 5-Hydroxytryptamine1A (5HT1A) receptors mediate increases in plasma glucose independent of corticosterone. Eur. J. Pharmacol. 2014, 745:91-97.
19. Mulder H., Franke B., van der Beek A., Arends J., Wilmink F.W., Egberts A.C., et al. The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. Pharmacogenomics J. 2006, 7:318-324.
20. Faris P.L., Eckert E.D., Kim S.W., Meller W.H., Pardo J.V., Goodale R.L., et al. Evidence for a vagal pathophysiology for bulimia nervosa and the accompanying depressive symptoms. J. Affect. Dis. 2006, 92:79-90.
21. Johnson B.A., Ait-Daoud N., Ma J.Z., Wang Y. Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals. Alcohol. Clin. Exp. Res. 2003, 27:1773-1779.
22. Rajkumar R., Mahesh R. The auspicious role of the 5-HT3 receptor in depression: a probable neuronal target. J. Psychopharmacol. 2010, 24:455-469.
23. Akhani S.P., Vishwakarma S.L., Goyal R.K. Anti-diabetic activity of Zingiber officinale in streptozotocin-induced type I diabetic rats. J. Pharm. Pharmacol. 2004, 56:101-105.
24. Carvalho F., Macêdo D., Bandeira I., Maldonado I., Salles L., Azevedo M.F., et al. Central 5-HT3 receptor stimulation by m-CPBG increases blood glucose in rats. Horm. Metab. Res. 2002, 34:55-61.
25. Heimes K., Feistel B., Verspohl E.J. Impact of the 5-HT3 receptor channel system for insulin secretion and interaction of ginger extracts. Eur. J. Pharmacol. 2009, 624:58-65.
26. Gupta D., Radhakrishnan M., Thangaraj D., Kurhe Y. Antidepressant and anti-anxiety like effects of 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide), a novel 5-HT3 receptor antagonist in acute and chronic neurobehavioral rodent models. Eur. J. Pharmacol. 2014, 735:59-67.
27. Ramamoorthy R., Radhakrishnan M., Borah M. Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behavior-based rodent models. Behav. Pharmacol. 2008, 19:29-40.
28. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 1977, 229:327-336.
29. Kelly J.P., Wyrnn A.S., Leonard B.E. Olfactory bulbectomized rat as a model of depression: an update. Pharmacol. Ther. 1997, 74:299-316.
30. File S.E. Animal models for predicting clinical efficacy of anxiolytic drugs: social behavior. Neuropsychobiology 1985, 13:55-62.
31. Chaudhury D., Walsh J.J., Friedman A.K., Juarez B., Ku S.M., Koo J.W., et al. Rapid regulation of depression-related behaviors by control of midbrain dopamine neurons. Nature 2012, 493:532-536.
32. Glowinski J., Iversen L.L. Regional studies of catecholamines in the rat brain-I. The disposition of [3H] norepinephrine, [3H] dopamine and [3H] dopa in various regions of the brain. J. Neurochem. 1966, 13:655-669.
33. Curzon G., Green A.R. Rapid method for the determination of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in small regions of rat brain. Br. J. Pharmacol. 1970, 39:653-655.
34. Kilpatrick G.J., Butler A., Burridge J., Oxford A.W. 1-(m-Chlorophenyl)-biguanide, a potent high affinity 5-HT3 receptor agonist. Eur. J. Pharmacol. 1990, 182:193-197.
35. Machado D.G., Bettio L.E.B., Cunha M.P., Capra J.C., Dalmarco J.B., Pizzolatti M.G., et al. Antidepressant-like effect of the extract of Rosmarinus officinalis in mice: involvement of the monoaminergic system. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:642-650.
36. Wayhs C.A.Y., Manfredini V., Sitta A., Deon M., Ribas G., Vanzin C., et al. Protein and lipid oxidative damage in streptozotocin-induced diabetic rats submitted to forced swimming test: the insulin and clonazepam effect. Metab. Brain Dis. 2010, 25:297-304.
37. Li J.X., France C.P. Food restriction and streptozotocin treatment decrease 5-HT1A and 5-HT2A receptor mediated behavioral effects in rats. Behav. Pharmacol. 2008, 19:292-297.
38. Miyata S., Hirano S., Kamei J. Diabetes attenuates the antidepressant-like effect mediated by the activation of 5-HT1A receptor in the mouse tail suspension test. Neuropsychopharmacology 2004, 29:461-469.
39. Aksu I., Ates M., Baykara B., Kiray M., Sisman A.R., Buyuk E., et al. Anxiety correlates to decreased blood and prefrontal cortex IGF-1 levels in streptozotocin induced diabetes. Neurosci. Lett. 2012, 531:176-181.
40. Gupta D., Radhakrishnan M., Kurhe Y. Insulin reverses anxiety-like behavior evoked by treptozotocin-induced diabetes in mice. Metab. Brain Dis. 2014, 29:737-746.
41. Ramanathan M., Jaiswal A.K., Bhattachayra S.K. Differential effects of diazepam on anxiety in streptozotocin induced diabetic and non-diabetic rats. Psychopharmacology (Berl) 1998, 135:361-367.
42. Hilakivi-Clarke L.A., Wozniak K.M., Durcan M.J., Linnoila M. Behavior of streptozotocin diabetic mice in test of exploration, locomotion, anxiety, depression and aggression. Physiol. Behav. 1990, 48:429-433.
43. Ho N., Balu D.T., Hilario M.R., Blendy J.A., Lucki I. Depressive phenotypes evoked by experimental diabetes are reversed by insulin. Physiol. Behav. 2012, 105:702-708.
44. Ressler K.J., Nemeroff C.B. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 2000, 12:2-19.
45. Manjarrez-Gutierrez G., Marquez R.H., Mejenes-Alvarez S.A., Godinez-Lopez T., Hernandez-R J. Functional change of the auditory cortex related to brain serotonergic neurotransmission in type 1 diabetic adolescents with and without depression. World J. Biol. Psychiatry 2009, 10:877-883.
46. Antony S., Kumar T.P., Kuruvilla K.P., George N., Paulose C.S. Decreased GABA receptor binding in the cerebral cortex of insulin induced hypoglycemic and streptozotocin induced diabetic rats. Neurochem. Res. 2010, 35:1516-1521.
47. Gomez R., Vargas C.R., Wajner M., Barros H.M. Lower in vivo brain extracellular GABA concentration in diabetic rats during forced swimming. Brain Res. 2003, 968:281-284.
48. Slattery D.A., Desrayaud S., Cryan J.F. GABAB receptor antagonist-mediated antidepressant-like behavior is serotonin-dependent. J. Pharmacol. Exp. Ther. 2005, 312:290-296.
49. Morales M., Bloom F.E. The 5-HT3 receptor is present in different subpopulations of GABAergic neurons in the rat telencephalon. J. Neurosci. 1997, 17:3157-3167.
50. Puig M.V., Santana N., Celada P., Mengod G., Artigas F. In vivo excitation of GABA interneurons in the medial prefrontal cortex through 5-HT3 receptors. Cereb. Cortex 2004, 14:1365-1375.
51. Koyama S., Matsumoto N., Kubo C., Akaike N. Presynaptic 5-HT3 receptor-mediated modulation of synaptic GABA release in the mechanically dissociated rat amygdala neurons. J. Physiol. 2000, 529:373-383.